Co-Diagnostics is augmenting its Logix Smart COVID-19 test kit to prepare for the flu season

Co-Diagnostics Inc (NASDAQ:CODX), a molecular diagnostics company, provided shareholders with an operational update on its CoPrimer technology-based Logix Smart COVID-19 test kit. In an update on Tuesday, the Salt Lake City, Utah-based company said that it was “augmenting” its COVID-19 test kit with a respiratory virus panel to prepare for the flu season. "In light of the upcoming flu season and the ongoing coronavirus pandemic, the company is augmenting our COVID-19 testing with our forthcoming respiratory virus panel, which will test for and differentiate between influenza A, influenza B and COVID-19, and will be introduced to our expanded customer base in the United States and across the world,” said the company. READ: Co-Diagnostics wins increased US patent protection for its CoPrimer technology used in its coronavirus test kit Co-Diagnostics also told shareholders that it continued to participate in successful joint government and private collaborations in several states. “The reach of the company's coronavirus test has also expanded to high-throughput laboratories which serve a nationwide customer base,” said the company. Co-Diagnostics said the sales generated by the collaborations and “important lab relationships” continue, and the need for “high quality, high volume” RT-PCR (or reverse-transcriptase polymerase chain reaction) tests like its Logix Smart COVID-19 test remains in “significant demand.”   “RT-PCR tests are recognized for their important role in detection of the SARS-CoV-2 virus, and the global demand for PCR-based diagnostics like our Logix Smart COVID-19 test kit continues,” noted the company. According the Centers for Disease Control and Prevention, RT-PCR remains the 'gold standard' for clinical diagnostic detection of SARS-CoV-2. RT-PCR also provides higher fast data throughput and sensitivity than antigen tests. The company added that Logix Smart COVID-19 tests now also work with self-administered, saliva-based collection kits that can be processed via high throughput protocols to return results without sacrificing accuracy. This allows the company to play its part in creating COVID-safe schools, COVID-safe businesses, and COVID-safe communities, said Co-Diagnostics. Contact the author Uttara Choudhury at uttara@proactiveinvestors.com Follow her on Twitter: @UttaraProactive